CCR5 and leukemia: A recent clinical study by Xu et al. via transplanting the CCR5-edited stem cells by CRISPR/SpCas9 to a patient with AIDS and leukemia, has been verified that the CCR5 edited cells could resist HIV-1 infection, for a short time suspension of HAART promoted the editing efficacy.